Drug discovery Startups
34 companies tagged Drug discovery, with their investors and founders.
Adventris is a biotechnology company developing cancer immunotherapy treatments.
1 investor
AtlasDiscovery develops foundation models of patient drug response trained on pre-clinical and clinical data to improve drug trial design and success rates. The company serves pharmaceutical and biotech firms by predicting human drug responses and enabling drug rescue and development in the biotech industry.
1 investor
Biocartesian provides optical pooled screening services for functional genomics research. The company uses its proprietary ARADIA technology to link microscopy-based cellular phenotypes with genetic perturbations, enabling researchers to conduct large-scale CRISPR screens and other genomic studies with visual, spatial, and live-cell readouts.
1 investor
EncepHeal develops small-molecule medications targeting the dopamine transporter to treat stimulant addiction, including cocaine and methamphetamine, for which no FDA-approved treatments currently exist. The company uses allosteric modulators designed to reduce drug cravings without the addictive potential of earlier dopamine-targeting approaches.
1 investor
Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.
1 investor
FlowDeploy provides a platform for bioinformaticians to build, execute, and share data analysis pipelines in the cloud using tools like Nextflow or Snakemake, with features including cloud cost controls, credential management, and a web interface for pipeline monitoring.
1 investor
Invitris develops cell-free protein synthesis platforms that enable rapid design, expression, and scalable production of complex proteins for biopharmaceuticals, industrial biotechnology, and agriculture.
1 investor
Oncobox provides genetic profiling of tumor samples to help oncologists select the most likely effective drug from existing targeted cancer therapies for individual patients with advanced cancer. The analysis examines tumor DNA, RNA, and molecular pathways to identify the most relevant drug targets and generates a clinical report recommending which treatments are most likely to work.
1 investor
Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.
1 investor
Relevium Medical is a biopharmaceutical company developing long-lasting treatments for chronic pain conditions, particularly osteoarthritis. The company focuses on therapeutic hydrogels and drug discovery for patients with debilitating pain.
1 investor